Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
Sponsor: Mayo Clinic
Summary
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
Official title: Pilot Study for the Use of Shortened Preemptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney, Heart, Lung and/or Pancreas) of Hepatitis C Viremic Donors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-09-10
Completion Date
2026-11-01
Last Updated
2025-12-17
Healthy Volunteers
No
Interventions
Mavyret
Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
Locations (1)
Mayo Clinic in Arizona
Phoenix, Arizona, United States